NASDAQ | VICL: 1.21  -0.06



Smith LR, et al. Clinical development of a cytomegalovirus DNA vaccine: From product concept to pivotal phase 3 trial. Vaccines. 2013 Sep;1(4):398-414. Doi: 10.3390/vaccines1040398.

Kulkarni V, et al. Vaccination with Vaxfectin adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 viremia. Hum Vaccin Immunother. 2013 Jul 2;9(10):2069-2080. Doi: 10.4161/hv.25442.

Smith LR, et al. Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Hum Vaccin Immunother. 2013 Jun 9;9(6):1333-1345. Doi: 10.4161/hv.24209.

Lin WH, et al. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins. J Virol 2013 Jun;87(12):6560-8. doi: 10.1128/JVI.00635-13..

Chuang I, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013 Feb 14;8(2):e55571. doi: 10.1371/journal.pone.0055571..

Kharfan-Dabaja MA, et al. Reanalysis of TransVax immunogenicity. Lancet Infect Dis 2013 Jan;13(1):18. doi: 10.1016/S1473-3099(12)70296-7.


Raviprakash K, et al. A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum Vaccin Immunother 2012 Dec 1;8(12):1764-8. doi: 10.4161/hv.21806. Epub 2012 Oct 2.

Doukas J, Rolland A. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther 2012 Dec;19(12):811-7. doi: 10.1038/cgt.2012.69. Epub 2012 Oct 5. Review.

Hartikka J, et al. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother 2012 Nov 1;8(11):1595-606. doi: 10.4161/hv.21225. Epub 2012 Aug 24.

Richie TL, et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Immunotherapy 2012 Nov 1; 8(11):1564-84. doi: 10.4161/hv.22129. Epub 2012 Nov 1.

Veselenak RL, et al. A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012 Nov 19;30 (49):7046-51. doi: 10.1016/j.vaccine.2012.09.057. Epub 2012 Oct 4.

Shlapobersky M, et al. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 2012 Jun;93(Pt 6):1305-15. doi: 10.1099/vir.0.040055-0. Epub 2012 Mar 7.

Kharfan-Dabaja MA, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012 Apr;12(4):290-9. doi: 10.1016/S1473-3099(11)70344-9. Epub 2012 Jan 10. Erratum in: Lancet Infect Dis. 2012 Apr;12(4):266.


Doukas J, et al. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®. Vaccine 2011 Jul 26;29(33):5443-52. doi: 10.1016/j.vaccine.2011.05.060. Epub 2011 Jun 17.

Ledgerwood J, et al. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. J Infect Dis 2011 203 1396-404.

Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: Allovectin-7®. Immunotherapy 2011;3 17-21.


Sullivan S et al. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Del 2010 7 1433-1446.

Bedikian AY et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010 20 218-226.

Sedegah M et al. Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine 2010; 28 3055-3065.

Smith LR et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28 2565-2572.

Soares HP, Lutzky J; Velimogene aliplasmid. Exp Opin Biol Ther 2010; 10 841-851.


Hartikka J et al. Vaxfectin®, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine 2009; 27 6399-6403.

Moss RB. Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Imm Based Ther Vacc 2009; 7 3.

Muller WJ et al. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol 2009; 90 1153-1163.

Schleiss M. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther 2009; 11 572-578.

Shlapobersky M et al. Vaxfectin®-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters. Vaccine 2009; 27 6404-6410.

Vilalta A et al. Analysis of biomarkers after intramuscular injection of Vaxfectin®-formulated hCMV gB plasmid DNA. Vaccine 2009; 27 7409-7417.

Ye M et al. Rapid development of a Vaxfectin®-adjuvanted DNA vaccine encoding pandemic swine-origin influenza A virus (H1N1) hemagglutinin. Gene Ther Reg 2009; 4 45-55.


Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Exp Opin Biol Ther 2008; 8 839-844.

Dery M, Bausch DG. A DNA vaccine for the prevention of Ebola virus infection. Curr Opin Mol Ther 2008; 10 285-293.

Go V, Pollard RB. A Cytomegalovirus Vaccine for Transplantation: Are We Closer? J Infect Dis 2008; 197 1631-3.

Hartikka J et al. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 2008; 10 770-782.

Horton H, Lalor P, Rolland A. IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol 2008; 423 361-372.

Lalor PA et al. Plasmid DNA-Based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/Vietnam/1203/04 (H5N1) Influenza Virus. J Infect Dis 2008; 197 1643-52.

Mahajan R et al. A TaqMan® Reverse Transcription Polymerase Chain Reaction (RT-PCR) In Vitro Potency Assay for Plasmid-based Vaccine Products. Mol Biotechnol 2008; 40 47-57.

Martin JE et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008; 26 6338-6343.

Pan CH et al. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 2008; 15 1214-1221.

Wloch MK et al. Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects. J Infect Dis 2008; 197 1634-42.


Abai AM et al. Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods 2007; 322 82-93.

Jiang G et al. Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malar J 2007; 6 135.

Jimenez GS et al. Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007; 3 157-164.

Kaslow DC. Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter. Hum Vaccin 2007; 3 1-7.

Martin JE et al. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. J Infect Dis 2007; 196 1732-1740.

Sandbulte MR et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4 e59.

Selinsky C et al. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human IgG antibodies to anthrax lethal factor antigen. Biologicals 2007; 35 123-129.

Tompkins SM et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13 426-435.

Vilalta A et al. Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge. Hum Gene Ther 2007; 18 763-771.


Dunachie SJ et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74 5933-5942.

Gonzalez R et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006; 16 521-526.

Hahn UK, Aichler M, Boehm R, Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 2006; 24 4595-4597.

Leamy VL et al. Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines. Hum Vaccin 2006; 2 113-118.

Margalith M, Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther 2006; 4 2.

Minke JM et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol 2006; 111 47-57.

Rolland A. Nuclear gene delivery: the Trojan horse approach. Expert Opin Drug Deliv 2006; 3 1-10.

Romano M et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006; 24 3353-3364.

Sedegah M et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24 1921-1927.


Hirsch-Lerner D et al. Effect of "helper lipid" on lipoplex electrostatics. Biochim Biophys Acta 2005; 1714 71-84.

Manthorpe M et al. Plasmid vaccines and therapeutics: from design to applications. Adv Biochem Eng Biotechnol 2005; 99 41-92.

Rolland A. Gene medicines: the end of the beginning? Adv Drug Deliv Rev 2005; 57 669-673.

Selinsky C et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 2005; 1 16-23.

Vilalta A et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 2005; 16 1143-1150.

Vilalta A et al. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum Gene Ther 2005; 16 1151-1156.

Yanagie H, Eriguchi M. [Gene therapy for liver metastasis of colon cancer]. Nippon Rinsho 2005; 63 Suppl 12 537-543.


Arpicco S et al. Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids. Farmaco 2004; 59 869-878.

Evans TG et al. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine 2004; 22 2626-2630.

Ferrari ME, Hermanson G, Rolland A. Development of anthrax DNA vaccines. Curr Opin Mol Ther 2004; 6 506-512.

Galanis E et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 2004; 101 2557-2566.

Geall AJ et al. Targeting malaria with polyamines. Bioconjug Chem 2004; 15 1161-1165.

Hermanson G et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004; 101 13601-13606.

Kaslow DC. A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. Trans R Soc Trop Med Hyg 2004; 98 593-601.

Li J et al. The immunoregulation of mice by somatic transgenic expression of porcine interleukin-6 gene and CpG sequence. Vet Res Commun 2004; 28 33-46.

Li X et al. [Modulation of immune response to Plasmodium falciparum apical membrane antigen 1 DNA vaccine by cytokine plasmids]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2004; 22 136-138.

Locher CP, Witt SA, Ashlock BM, Levy JA. Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA Cell Biol 2004; 23 107-110.


Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7®) in patients with metastatic melanoma. Expert Opin Biol Ther 2003; 3 377-384.

Coker C, Majid M, Radulovic S. Development of Rickettsia prowazekii DNA vaccine: cloning strategies. Ann N Y Acad Sci 2003; 990 757-764.

Dai B et al. [Analysis of CpG motifs in endoflagellar gene (flaB2) and expression vector (VR1012) of leptospiral DNA vaccine]. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34 1-4.

Dumonteil E, Maria Jesus RS, Javier EO, Maria del Rosario GM. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 2003; 21 2161-2168.

Fischer L et al. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 2003; 21 4593-4596.

Fischer L et al. Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge. Vaccine 2003; 21 1099-1102.

Glazyrin AL, Kan-Mitchell J, Mitchell ML. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells. Cancer Immunol Immunother 2003; 52 171-178.

Hellum M et al. Photochemically enhanced gene delivery with cationic lipid formulations. Photochem Photobiol Sci 2003; 2 407-411.

Nukuzuma C, Ajiro N, Wheeler CJ, Konishi E. Enhancing effect of Vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol 2003; 16 183-189.

Rainczuk A, Scorza T, Smooker PM, Spithill TW. Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors. Infect Immun 2003; 71 4506-4515.

Rainczuk A et al. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol. Vaccine 2003; 21 3030-3042.

Rath A et al. Characterization of immune response in mice to plasmid DNA encoding dog zona pellucida glycoprotein-3. Vaccine 2003; 21 1913-1923.


D'Souza S et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002; 70 3681-3688.

Ferrari ME, Rusalov D, Enas J, Wheeler CJ. Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes. Nucleic Acids Res 2002; 30 1808-1816.

Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther 2002; 4 80-87.

Gaucheron J, Santaella C, Vierling P. Transfection with fluorinated lipoplexes based on fluorinated analogues of DOTMA, DMRIE and DPPES. Biochim Biophys Acta 2002; 1564 349-358.

Hogset A et al. Photochemical transfection: a technology for efficient light-directed gene delivery. Somat Cell Mol Genet 2002; 27 97-113.

Hong YS et al. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 2002; 21 1188-1200.

Kaslow DC. Transmission-blocking vaccines. Chem Immunol 2002; 80 287-307.

Ota T, Maeda M, Tatsuka M. Cationic liposomes with plasmid DNA influence cancer metastatic capability. Anticancer Res 2002; 22 4049-4052.

Prasmickaite L, Hogset A, Berg K. The role of the cell cycle on the efficiency of photochemical gene transfection. Biochim Biophys Acta 2002; 1570 210-218.

Rath A et al. Antibodies generated in response to plasmid DNA encoding zona pellucida glycoprotein-B inhibit in vitro human sperm-egg binding. Mol Reprod Dev 2002; 62 525-533.

Sankar V et al. Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses. Oral Dis 2002; 8 275-281.

Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002; 13 761-773.

Singh G, Parker S, Hobart P. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma. Vaccine 2002; 20 1400-1411.

Timmerman JM et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62 5845-5852.

Uchida E, Mizuguchi H, Ishii-Watabe A, Hayakawa T. Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. Biol Pharm Bull 2002; 25 891-897.

Vellon L et al. Enhanced uptake of antisense oligonucleotides using cationic liposomes and the apoptotic effect of idarubicin in K-562 cell line. Leuk Res 2002; 26 669-676.

Vilalta A, Whitlow V, Martin T. Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal Biochem 2002; 301 151-153.

Zhang T, Tsang TC, Harris DT. Comparison of cis and trans tat gene expression in HIV LTR-based amplifier vectors. Biotechniques 2002; 33 1146-1151.


Baccaglini L et al. Cationic liposome-mediated gene transfer to rat salivary epithelial cells in vitro and in vivo. J Gene Med 2001; 3 82-90.

Belldegrun A et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12 883-892.

Daniels GA, Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Curr Opin Mol Ther 2001; 3 70-76.

Ferrari ME, Rusalov D, Enas J, Wheeler CJ. Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity. Nucleic Acids Res 2001; 29 1539-1548.

Fleeton MN et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001; 183 1395-1398.

Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release 2001; 73 401-416.

Gleich LL et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001; 127 775-779.

Hartikka J et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4 407-415.

Hartikka J et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001; 19 1911-1923.

Kaiser S, Toborek M. Liposome-mediated high-efficiency transfection of human endothelial cells. J Vasc Res 2001; 38 133-143. Kaushik A. Leuvectin Vical Inc. Curr Opin Investig Drugs 2001; 2 976-981.

Madry H, Reszka R, Bohlender J, Wagner J. Efficacy of cationic liposome-mediated gene transfer to mesangial cells in vitro and in vivo. J Mol Med 2001; 79 184-189.

Parker SE et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001; 8 1011-1023.

Pleyer U et al. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res 2001; 73 1-7.

Pupa SM et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 2001; 8 75-79.

Reyes L et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 2001; 19 3778-3786.

Sanchez GI et al. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infect Immun 2001; 69 3897-3905.

Schleef RR, Olman MA, Miles LA, Chuang JL. Modulating the fibrinolytic system of peripheral blood mononuclear cells with adenovirus. Hum Gene Ther 2001; 12 439-445.

Scholl FG et al. Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant 2001; 20 322-329.

Simberg D et al. Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. J Biol Chem 2001; 276 47453-47459.

Stopeck AT et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7 2285-2291.

Suzuki S et al. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol Int 2001; 67 216-223.

Ushijima K et al. Anti-HIV-1 activity of an antisense phosphorothioate oligonucleotide bearing imidazole and primary amine groups. Bioorg Med Chem 2001; 9 2165-2169.

Vilalta A, Wu D, Margalith M, Hobart P. Rabbit EPO gene and cDNA: expression of rabbit EPO after intramuscular injection of pDNA. Biochem Biophys Res Commun 2001; 284 823-827.

Yonezawa T et al. Detection of transgene in progeny at different developmental stages following testis-mediated gene transfer. Mol Reprod Dev 2001; 60 196-201.


Abul-Hassan K, Walmsley R, Boulton M. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr Eye Res 2000; 20 361-366.

Aujame L, Seguin D, Droy C, Hessler C. Experimental design optimization of filamentous phage transfection into mammalian cells by cationic lipids. Biotechniques 2000; 28 1202-1206, 1208, 1210 passim.

Blanton JR, Jr. et al. Plasmid transfection and retroviral transduction of porcine muscle cells for cell-mediated gene transfer. J Anim Sci 2000; 78 909-918.

Clark PR, Stopeck AT, Parker SE, Hersh EM. Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft. Cell Immunol 2000; 204 96-104.

Clark PR et al. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA. Cancer Gene Ther 2000; 7 853-860.

Clayton J, Middlebrook JL. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000; 18 1855-1862.

Dai B et al. Protection against leptospirosis by immunization with plasmid DNA encoding 33 kDa endoflagellin of L. interrogans serovar Lai. Chin Med Sci J 2000; 15 14-19.

Dassow H, Lassner D, Remke H, Preiss R. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules. Int J Clin Pharmacol Ther 2000; 38 209-216.

Dumonteil E et al. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev Biol (Basel) 2000; 104 135-141.

Gleich LL. Gene therapy for head and neck cancer. Laryngoscope 2000; 110 708-726.

Gutheil JC. Novel immunologic and biologic therapies for breast cancer. Curr Oncol Rep 2000; 2 582-586.

Gutheil JC et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6 3056-3061.

Hartikka J et al. Sodium phosphate enhances plasmid DNA expression in vivo. Gene Ther 2000; 7 1171-1182.

Hoffman DM, Figlin RA. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000; 18 152-156.

Horiguchi Y et al. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 2000; 7 844-851.

Kunitomi M et al. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene. Jpn J Cancer Res 2000; 91 343-350.

Larchian WA et al. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res 2000; 6 2913-2920.

Le TP et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18 1893-1901.

Madry H, Trippel SB. Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Ther 2000; 7 286-291.

Mizuta T et al. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. Biochem Biophys Res Commun 2000; 279 158-161.

Norman JA et al. DNA vaccine encoding PSMA significantly reduces tumor growth and prolongs life in mice with TRAMP tumors. Clinical Cancer Research 2000; 6 511.

Sedegah M et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000; 164 5905-5912.

Takagi T et al. Effect of cationic liposomes on intracellular trafficking and efficacy of antisense oligonucleotides in mouse peritoneal macrophages. J Drug Target 2000; 7 363-371.

Thompson JA et al. Phase II trial of plasmid DNA/lipid (leuvectin) immunotherapy in patients with metastatic renal cell carcinoma. Clinical Cancer Research 2000; 6 517.

Vellon L, Cuello T, Gargallo P, Larripa I. [Antisense oligonucleotides increase the apoptotic effect of idarubicin in K-562 cell line]. Medicina (B Aires) 2000; 60 143-145.

Zelphati O et al. PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA. Biotechniques 2000; 28 304-310, 312-304, 316.

Zhang YY et al. Immunogenicity of plasmid DNA encoding the 62 kDa fragment of Schistosoma japonicum myosin. Vaccine 2000; 18 2102-2109.


Abai AM, Hobart PM, Barnhart KM. Insulin delivery with plasmid DNA. Hum Gene Ther 1999; 10 2637-2649.

Abai AM, Hobart PM, Norman J. Gene therapy for type-1 diabetes. Diabetes 1999; 48 51.

Akporiaye ET, Hersh E. Clinical aspects of intratumoral gene therapy. Curr Opin Mol Ther 1999; 1 443-453.

Anderson KL et al. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. Blood 1999; 94 2310-2318.

Barnhart KM. Simplified PCR-mediated, linker-scanning mutagenesis. Biotechniques 1999; 26 624-626.

Cameron FH et al. A transfection compound series based on a versatile Tris linkage. Biochim Biophys Acta 1999; 1417 37-50.

Chang Y, Prud'homme GJ. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J Gene Med 1999; 1 415-423.

Clayman GL, Dreiling L. Local delivery for gene therapy. Curr Oncol Rep 1999; 1 138-143.

Fernandes J et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999; 154 1159-1169.

Figlin RA, Parker SE, Horton HM. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma. Curr Opin Mol Ther 1999; 1 271-278.

Galanis E et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17 3313-3323.

Hasan UA et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999; 229 1-22.

Hermanson GG, Singh G, Hobart P. Immunogenicity and protective effects of coadministered cytokine and chemokine plasmid DNAs in a murine B-cell lymphoma model. Cancer Gene Therapy 1999; 6 112.

Hernandez P, Hof R, Parker S, Horton H. Systemic treatment of cancer by intramuscular injection of an interferon-alpha-expressing plasmid DNA. Cancer Gene Therapy 1999; 6 108.

Hersh E et al. Long-term follow-up of melanoma patients who have received Allovectin-7 gene therapy treatment. Cancer Gene Therapy 1999; 6 92.

Horton HM, Hernandez P, Parker SE, Barnhart KM. Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res 1999; 59 4064-4068.

Horton HM, Parker SE, Wloch MK, Norman JA. DNA vaccines for cancer therapy. Expert Opin Investig Drugs 1999; 8 2017-2026.

Horton HM et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96 1553-1558.

Horton HM et al. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol 1999; 163 6378-6385.

Ilan Y. Technology evaluation: naked DNA. Curr Opin Mol Ther 1999; 1 116-120.

Kisich KO, Malone RW, Feldstein PA, Erickson KL. Specific inhibition of macrophage TNF-alpha expression by in vivo ribozyme treatment. J Immunol 1999; 163 2008-2016.

Klavinskis LS, Barnfield C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999; 162 254-262.

Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999; 17 19-25.

Li K, Stewart DJ, Ward HJ. Technology evaluation: gene therapy (FGF-5), Vical. Curr Opin Mol Ther 1999; 1 260-265.

Martin T et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999; 10 759-768.

Miao J et al. [Humoral immune response in mice to hybrid nucleic acid vaccines containing Plasmodium falciparum merozoite surface protein 1 block 17-based gene]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1999; 17 302-304.

Neglia F et al. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther 1999; 6 349-357.

Ochiya T et al. Evaluation of cationic liposome suitable for gene transfer into pregnant animals. Biochem Biophys Res Commun 1999; 258 358-365.

Oku N. Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Deliv Rev 1999; 37 53-61.

Pal S et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999; 17 459-465.

Parker SE et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999; 10 741-758.

Pereira-Chioccola VL et al. Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein. Parasite Immunol 1999; 21 103-110.

Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 1999; 6 771-777.

Ramasamy R et al. Mammalian cell expression of malaria merozoite surface proteins and experimental DNA and RNA immunisation. Biochim Biophys Acta 1999; 1453 1-13.

Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5 2766-2772.

Schreiber A et al. Effect of Leuvectin, an interleukin-2 gene therapy agent, on prostate-specific antigen (PSA) in patients undergoing neoadjuvant or adjuvant gene therapy for prostate cancer. Cancer Gene Therapy 1999; 6 91.

Smith GJ, 3rd et al. Fast and accurate method for quantitating E. coli host-cell DNA contamination in plasmid DNA preparations. Biotechniques 1999; 26 518-522, 524, 526.

Smooker PM et al. Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression. Parasite Immunol 1999; 21 357-364.

Wloch MK et al. Human gp100 plasmid DNA vaccination induces cytotoxic T lymphocytes (CTLs) that lyse interferon-alpha (IFN-alpha)-treated but not untreated mouse melanoma cells. Cancer Gene Therapy 1999; 6 113.

You Z et al. [Immunogenicity and immunoprotection of a leptospiral DNA vaccine]. Hua Xi Yi Ke Da Xue Xue Bao 1999; 30 128-132.

Zelphati O, Liang XW, Hobart P, Felgner PL. Gene chemistry: Functionally and conformationally intact fluorescent plasmid DNA. Human Gene Therapy 1999; 10 15-24.


Anchordoquy TJ, Girouard LG, Carpenter JF, Kroll DJ. Stability of lipid/DNA complexes during agitation and freeze-thawing. J Pharm Sci 1998; 87 1046-1051.

Barnhart KM et al. Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study. Hum Gene Ther 1998; 9 2545-2553.

Campain JA et al. Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi's sarcoma cell lines. Cancer Gene Ther 1998; 5 131-143.

DeBruyne LA et al. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther 1998; 5 1079-1087.

Doolan DL et al. DNA vaccination as an approach to malaria control: current status and strategies. Curr Top Microbiol Immunol 1998; 226 37-56.

Felgner PL, Rolland A. Preface. Adv Drug Deliv Rev 1998; 30 1-3.

Ferrari ME et al. Analytical methods for the characterization of cationic lipid-nucleic acid complexes. Hum Gene Ther 1998; 9 341-351.

Gleich LL et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 1998; 124 1097-1104.

Hedstrom RC et al. In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines. Int J Mol Med 1998; 2 29-38.

Hernandez P, Anderson D, Parker S, Horton H. A novel plasmid DNA gene therapy for treatment of metastatic disease. Cancer Gene Therapy 1998; 5 D11.

Horton HM et al. Development of a novel plasmid DNA gene therapy for treatment of distant primary and metastatic tumors in mice. Cancer Gene Therapy 1998; 5 28.

Huang CY et al. Lipitoids--novel cationic lipids for cellular delivery of plasmid DNA in vitro. Chem Biol 1998; 5 345-354.

Konopka K et al. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta 1998; 1372 55-68.

Lahijani R et al. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive polymerase chain reaction and enzyme-linked immunosorbent assay. Hum Gene Ther 1998; 9 1173-1180.

McCluskie MJ et al. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev 1998; 8 401-414.

Murphy JE et al. A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. Proc Natl Acad Sci USA 1998; 95 1517-1522.

Nabel GJ, Hobart P. Keystone symposia on: molecular and cellular biology of gene therapy and synthetic non-viral gene delivery systems, Keystone, CO, USA, January 19-25, 1998. Biochim Biophys Acta 1998; 1378 R19-26.

Raghupathi R et al. BCL-2 overexpression attenuates cortical cell loss after traumatic brain injury in transgenic mice. Journal Of Cerebral Blood Flow And Metabolism 1998; 18 1259-1269.

Rolland A, Felgner PL. Non-viral gene delivery systems - Preface. Advanced Drug Delivery Reviews 1998; 30 1-3.

Saffran DC et al. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Cancer Gene Ther 1998; 5 321-330.

Sawai K et al. A novel method of cell-specific mRNA transfection. Mol Genet Metab 1998; 64 44-51.

Sedegah M et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998; 95 7648-7653.

Stopeck AT et al. Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther 1998; 5 119-126.

Surovoy A, Flechsler I, Jung G. A novel series of serum-resistant lipoaminoacid compounds for cellular delivery of plasmid DNA. Adv Exp Med Biol 1998; 451 461-467.

Wang R et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282 476-480.

Wang R et al. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun 1998; 66 4193-4202.

Weiss WR et al. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161 2325-2332.

Zelphati O et al. Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther 1998; 5 1272-1282.


Barnfield C et al. Characterization of gene expression following intranasal immunization with nucleic acid. Biochem Soc Trans 1997; 25 335S.

Doh SG et al. Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA. Gene Ther 1997; 4 648-663.

Doolan DL et al. DNA vaccines for malaria: the past, the present, & the future. Indian J Med Res 1997; 106 109-119.

Duncan JE, Whitsett JA, Horowitz AD. Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum Gene Ther 1997; 8 431-438.

Eastman SJ et al. Biophysical characterization of cationic lipid: DNA complexes. Biochim Biophys Acta 1997; 1325 41-62.

El Ouahabi A et al. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 1997; 414 187-192.

Fasbender A, Zabner J, Zeiher BG, Welsh MJ. A low rate of cell proliferation and reduced DNA uptake limit cationic lipid-mediated gene transfer to primary cultures of ciliated human airway epithelia. Gene Ther 1997; 4 1173-1180.

Felgner JH. Separation and quantitation of cationic liposome components by high performance liquid chromatography with evaporative light-scattering detection. Pharm Res 1997; 14 1269-1271.

Felgner PL. Nonviral strategies for gene therapy. Sci Am 1997; 276 102-106.

Felgner PL et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8 511-512.

Gao L et al. Mucosal delivery of nucleic acid elicits both cellular and humoral immunity. Biochem Soc Trans 1997; 25 336S.

Gramzinski RA et al. Malaria DNA vaccines in Aotus monkeys. Vaccine 1997; 15 913-915.

Hedstrom RC et al. The development of a multivalent DNA vaccine for malaria. Springer Semin Immunopathol 1997; 19 147-159.

Hersh EM, Stopeck AT. Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 1997; 3 2623-2629.

Hersh EM, Stopeck AT. Recent advances in the treatment of malignant melanoma with gene therapy. Mol Med 1997; 3 636-651.

Hersh EM et al. Phase II study of intratumoral injection of HLA-B7/beta 2M plasmid DNA-cationic lipid complex (Allovectin-7) therapy for metastatic malignant melanoma (MMM). Cancer Gene Therapy 1997; 4 124.

Hoffman SL et al. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine 1997; 15 842-845.

Hoffman SL et al. Toward clinical trials of DNA vaccines against malaria. Immunol Cell Biol 1997; 75 376-381.

Horton H et al. Gene therapy of ovarian cancer via IL-2 plasmid DNA and cationic lipid. Cancer Gene Therapy 1997; 4 149.

Hsiao M et al. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival. Biochem Biophys Res Commun 1997; 233 359-364.

Klavinskis LS et al. Mucosal immunization with DNA-liposome complexes. Vaccine 1997; 15 818-820.

Kochel T et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997; 15 547-552.

Konopka K, Harrison GS, Felgner PL, Duzgunes N. Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin a genes in HeLa cells infected with or expressing HIV. Biochim Biophys Acta 1997; 1356 185-197.

Luke CJ, Carner K, Liang X, Barbour AG. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 1997; 175 91-97.

Marquet M, Horn NA, Meek JA. Characterization of plasmid DNA vectors for use in human gene therapy.1. Biopharm-The Technology & Business Of Biopharmaceuticals 1997; 10 40-45.

Norman JA et al. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine 1997; 15 801-803.

Parker SE, Ducharme S, Norman J, Wheeler CJ. Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum Gene Ther 1997; 8 393-401.

Rodman DM et al. In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am J Respir Cell Mol Biol 1997; 16 640-649.

Rubin J et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4 419-425.

Rubin J et al. Phase I/II trial of the IL-2 DNA/DMRIE/DOPE lipid complex as an immunotherapeutic agent by direct gene transfer in patients with advanced melanoma, renal cell carcinoma, and sarcoma. Cancer Gene Therapy 1997; 4 125.

Snyder DS et al. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol Blood Marrow Transplant 1997; 3 179-186.

Stopeck AT et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15 341-349.

Tanner FC, Carr DP, Nabel GJ, Nabel EG. Transfection of human endothelial cells. Cardiovasc Res 1997; 35 522-528.

Teifel M, Heine LT, Milbredt S, Friedl P. Optimization of transfection of human endothelial cells. Endothelium 1997; 5 21-35.

Waddill W, 3rd et al. Human gene therapy for melanoma: CT-guided interstitial injection. AJR Am J Roentgenol 1997; 169 63-67.

Zuidam NJ, Barenholz Y. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin. Biochim Biophys Acta 1997; 1329 211-222.


Bebok Z et al. Efficiency of plasmid delivery and expression after lipid-mediated gene transfer to human cells in vitro. J Pharmacol Exp Ther 1996; 279 1462-1469.

Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996; 173 800-807.

Doolan DL et al. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996; 183 1739-1746.

Felgner PL. Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther 1996; 7 1791-1793.

Gardner MJ et al. DNA vaccines against malaria: immunogenicity and protection in a rodent model. J Pharm Sci 1996; 85 1294-1300.

Hartikka J et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 7 1205-1217.

Konopka K, Pretzer E, Felgner PL, Duzgunes N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim Biophys Acta 1996; 1312 186-196.

Lahijani R et al. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 1996; 7 1971-1980.

Liang X et al. Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Gene Ther 1996; 3 350-356.

McCarthy M. DNA vaccination: a direct line to the immune system. Lancet 1996; 348 1232.

Nabel GJ et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996; 93 15388-15393.

Oku N et al. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim Biophys Acta 1996; 1280 149-154.

Parker SE et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996; 3 175-185.

Schwarz LA et al. Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 1996; 7 731-741.

Stephan DJ et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 1996; 7 1803-1812.

Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2 1038-1041.

Tripathy SK et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93 10876-10880.

Wheeler CJ et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci USA 1996; 93 11454-11459.

Wheeler CJ et al. Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim Biophys Acta 1996; 1280 1-11.

Zhu J et al. A continuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Ther 1996; 3 472-476.


Fasbender AJ, Zabner J, Welsh MJ. Optimization of cationic lipid-mediated gene transfer to airway epithelia. Am J Physiol 1995; 269 L45-51.

Felgner PL, Zaugg RH, Norman JA. Synthetic recombinant DNA delivery for cancer therapeutics. Cancer Gene Ther 1995; 2 61-65.

Felgner PL et al. Improved cationic lipid formulations for in vivo gene therapy. Ann N Y Acad Sci 1995; 772 126-139.

Harrison GS et al. Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. Biotechniques 1995; 19 816-823.

Hoffman SL et al. Nucleic acid malaria vaccines. Current status and potential. Ann N Y Acad Sci 1995; 772 88-94.

Horn NA, Meek JA, Budahazi G, Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 1995; 6 565-573.

Lew D et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6 553-564.

Logan JJ et al. Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Ther 1995; 2 38-49.

Marquet M, Horn NA, Meek JA. Process Development for the Manufacture of Plasmid DNA Vectors for Use in Gene Therapy. BioPharm 1995; 8 26-37.

Mor G et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 1995; 155 2039-2046.

Norman JA et al. Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial. Hum Gene Ther 1995; 6 549-550.

Parker SE et al. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995; 6 575-590.

Zabner J et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270 18997-19007.


Abai A, Kuwhara-Rundell A, Margalith M, Morrow J, Parker SE, Rhodes GH. Coinjection of the Genes for Interlukin-2 and Antigen does not Increase Humoral Immune Response. In: Norrby E BF, Chanock RM, Ginsberg HS (ed). Vaccines 94. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1994, pp. 77-81.

Felgner JH et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269 2550-2561.

Nabel GJ et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994; 5 57-77.

Plautz GE et al. Direct gene transfer for the understanding and treatment of human disease. Ann N Y Acad Sci 1994; 716 144-153.

Raz E et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91 9519-9523.

Raz E, Carson DA, Rhodes GH, Abai AM, Tsai YJ, Wheeler CJ, Morrow J, Felgner PL, Baird SM. Cationic Lipids Inhibit Intradermal Genetic Vaccination. In: Norrby E BF, Chanock RM, Ginsberg HS (ed). Vaccines 94. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1994, pp. 71-75.

Rhodes GH et al. Characterization of humoral immunity after DNA injection. Dev Biol Stand 1994; 82 229-236.

Schmid S, Rhodes G, Morrow J, Hoffman SL, Kang AS. Nucleic acid vaccines against the preerythrocytic stage of rodent malaria Plasmodium yoelii. Cold Spring Harbor Symposium, October 1994 (abstract).

Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994; 91 9866-9870.

Sorscher EJ et al. Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway. Hum Gene Ther 1994; 5 1259-1277.

Vahlsing HL et al. Immunization with plasmid DNA using a pneumatic gun. J Immunol Methods 1994; 175 11-22.

Vogelzang NJ, Lestingi TM, Sudakoff G, Kradjian SA. Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum Gene Ther 1994; 5 1357-1370.

Zhou X et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994; 12 1510-1514.


Cohen J. Naked DNA points way to vaccines. Science 1993; 259 1691-1692.

Duzgunes N, Felgner PL. Intracellular delivery of nucleic acids and transcription factors by cationic liposomes. Methods Enzymol 1993; 221 303-306.

Dwarki VJ, Malone RW, Verma IM. Cationic liposome-mediated RNA transfection. Methods Enzymol 1993; 217 644-654.

Felgner PL. Genes in a bottle. Lab Invest 1993; 68 1-3.

Liu M, Ulmer JB, Friedman A, Martinex D, Hawe LA, DeWitt CM, Leander KR, Shi X-P, Montogomery DL, Donnelly JJ, Parker S, Felgner P, Felgner J. Immunization with DNA Encoding a Conserved Internal Viral Protein Results in Protection from Morbidity and Mortality Due to Challenge with Influenza A in Mice. In: Ginsberg HS BF, Chanock RM, Lerner RA (ed). Vaccines 93. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1993, pp. 343-346.

Manthorpe M et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 1993; 4 419-431.

Nabel GJ, Felgner PL. Direct gene transfer for immunotherapy and immunization. Trends Biotechnol 1993; 11 211-215.

Nabel GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90 11307-11311.

Rhodes GH et al. Injection of expression vectors containing viral genes induces cellular, humoral and protective immunity. In: Ginsberg HS (ed). Vaccines 93. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1993, pp. 137-141.

San H et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4 781-788.

Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259 1745-1749.

Yankauckas MA et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993; 12 771-776.


Jiao S et al. Persistence of plasmid DNA and expression in rat brain cells in vivo. Exp Neurol 1992; 115 400-413.

Kumar R, Gardner MF, Richman DD, Hostetler KY. Equal inhibition of HIV replication by stereoisomers of phosphatidyl-azidothymidine. Lack of stereospecificity of lysosomal phospholipase A1. J Biol Chem 1992; 267 20288-20292.

Nabel EG, Plautz G, Nabel GJ. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci USA 1992; 89 5157-5161.


Felgner PL, Rhodes G. Gene therapeutics. Nature 1991; 349 351-352.

King DH. Fluorinated pyrimidines: a new change for old drugs. Transplant Proc 1991; 23 168-170.


Hostetler KY et al. Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J Biol Chem 1990; 265 6112-6117.

Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247 1465-1468.


Duzgunes N, Goldstein JA, Friend DS, Felgner PL. Fusion of liposomes containing a novel cationic lipid, N- [2,3-(dioleyloxy)propyl]-N,N,N-trimethylammonium: induction by multivalent anions and asymmetric fusion with acidic phospholipid vesicles. Biochemistry 1989; 28 9179-9184.

Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989; 337 387-388.

Felgner PL, Holm M, Chan H. Cationic liposome mediated transfection. Proc West Pharmacol Soc 1989; 32 115-121.

Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86 6077-6081.


Felgner PL et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84 7413-7417.

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.